NCT00117247

Brief Summary

The purpose of this study is to evaluate the single dose pharmacokinetics (PK) of subcutaneous (SC) darbepoetin alfa in subjects with congestive heart failure (CHF) and anemia.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
Completed

Started Jun 2002

Typical duration for phase_1

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2002

Completed
2.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2004

Completed
12 months until next milestone

First Submitted

Initial submission to the registry

June 30, 2005

Completed
6 days until next milestone

First Posted

Study publicly available on registry

July 6, 2005

Completed
Last Updated

October 16, 2009

Status Verified

October 1, 2009

First QC Date

June 30, 2005

Last Update Submit

October 15, 2009

Conditions

Keywords

Heart Failure

Outcome Measures

Primary Outcomes (1)

  • Pharmacokinetic profiling of Aranesp® in HF pts

Secondary Outcomes (1)

  • Pharmacodynamic responses (hgb) following Aranesp® administration in HF patients

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Links

MeSH Terms

Conditions

AnemiaHeart Failure

Interventions

Darbepoetin alfa

Condition Hierarchy (Ancestors)

Hematologic DiseasesHemic and Lymphatic DiseasesHeart DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

ErythropoietinColony-Stimulating FactorsGlycoproteinsGlycoconjugatesCarbohydratesProteinsAmino Acids, Peptides, and Proteins

Study Officials

  • MD

    Amgen

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

June 30, 2005

First Posted

July 6, 2005

Study Start

June 1, 2002

Study Completion

July 1, 2004

Last Updated

October 16, 2009

Record last verified: 2009-10